** Shares of drugmaker PTC Therapeutics PTCT.O fall 1% to $54.38
** PTCT says the European Commission has decided not to renew marketing authorization for the company's muscle-wasting disorder drug, Translarna, and that the treatment will no longer be available for sale in the EU
** The drug had received conditional approval in EU in 2014 to treat children aged five years and older who can walk and are afflicted with Duchenne muscular dystrophy
** Company says it plans to work with countries individually to maintain commercial availability of the drug where possible
** TD Cowen analyst Joseph Thome estimates Translarna to generate $192 million in sales for 2025, with a "minimal contribution from the EU"
** Shares have gained 86.8% in the last 12 months, as of last close
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。